Assessing Azithromycin Distribution in Routine Healthcare Visits for Infant Mortality Reduction
|
Reviewed & translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on March 13th, 2024
|
The World Health Organization advocates for the biannual mass distribution of azithromycin to infants under 1 year old residing in regions with elevated child mortality rates. These widespread health interventions have demonstrated a 25% reduction in mortality risk. However, implementing such large-scale programs necessitates extensive logistical coordination. Consequently, a study was conducted to evaluate whether administering azithromycin during routine visits could yield comparable outcomes.
The study was conducted in Burkina Faso between 2019 and 2022, and it included 32,877 infants between the ages of 5 and 12 weeks old. These infants were not allergic to antibiotics in the macrolide group, and either medication or placebo was randomly assigned to the children while they attended their routine healthcare visit. Azithromycin was administered orally at a dose of 20 mg per kilogram of body weight. By the end of the study, the researchers observed that there was no difference between the mortality rates between the children who were given azithromycin and placebo. The contradictory results can be explained by the difference in health status of children who visit the clinic in this trial and children in the general community that were included in other studies. In addition, the proportion of underweight children in this study was significantly higher than the average population.
The study was conducted in Burkina Faso between 2019 and 2022, and it included 32,877 infants between the ages of 5 and 12 weeks old. These infants were not allergic to antibiotics in the macrolide group, and either medication or placebo was randomly assigned to the children while they attended their routine healthcare visit. Azithromycin was administered orally at a dose of 20 mg per kilogram of body weight. By the end of the study, the researchers observed that there was no difference between the mortality rates between the children who were given azithromycin and placebo. The contradictory results can be explained by the difference in health status of children who visit the clinic in this trial and children in the general community that were included in other studies. In addition, the proportion of underweight children in this study was significantly higher than the average population.